Triaging and Prioritizing Patients with Multiple Myeloma

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®

May 6th 2024

Daratumumab Combo Yields MRD-Negative Status in Transplant-Eligible Myeloma

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Chris Ryan

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD

August 14th 2023

Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Ryan Scott

MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma

Isatuximab, bortezomib, lenalidomide, and dexamethasone prolonged PFS vs bortezomib, lenalidomide, and dexamethasone, in a subsect of patients with multiple myeloma.

Brielle Benyon

June 3rd 2024

Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials

Similar outcomes were noted when linvoseltamab and teclistamab were analyzed as treatments for patients with relapsed/refractory multiple myeloma.

Related Content

Zachary M. Avigan, MD;Joshua Richter, MD

June 14th 2024

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

The June Hot Topics focuses on the challenges venetoclax regimens have faced in multiple myeloma trials.

Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®

May 6th 2024

Daratumumab Combo Yields MRD-Negative Status in Transplant-Eligible Myeloma

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Chris Ryan

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

Data from the PERSEUS trial also show that responses deepened over time in both arms among patients with transplant-eligible multiple myeloma.

Joselle Cook, MBBS, Mayo Clinic;Matthew James Pianko, MD;Luciano Costa, MD, PhD;Timothy Schmidt, MD

August 14th 2023

Prolonged PFS Observed in Isatuximab Combo in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Ryan Scott

MAIC Study Finds Similar Results With Linvoseltamab/Teclistamab in R/R Multiple Myeloma

Isatuximab, bortezomib, lenalidomide, and dexamethasone prolonged PFS vs bortezomib, lenalidomide, and dexamethasone, in a subsect of patients with multiple myeloma.

Brielle Benyon

June 3rd 2024